SLC5A2 and hydrops fetalis: Furthermore, SGLT2-Is demonstrated a risk reduction in the composite outcome of CVD death/HF hospitalisation in North America and Europe, but no strong evidence of effects was found in other regions (Europe, South/Central America, Asia/Pacific and Africa).